Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00001238 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 335 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor

    18 amendments

    18 re-verifications since 2025-09-10, no change to tracked fields

    v318-v335

  2. Minor

    Eligibility criteria shortened, about 26 words

    Study description revised

    Show what changed: Eligibility criteria
    INCLUSION CRITERIA: Participants must be greater than or equal to 2 years of age. All patientsparticipants and guardians (for children younger than 18 years of age) m [...] is study before any protocol related studies are performed. Patients under the age of 18 but who are age 13 or older will be asked to sign an assent document prior to participation. Criteria for Acceptance into this Study (i.e., Disease Categ [...] ogic relatives) Subject Category A: Category A will include patientsindividuals, and biologic relatives, who may or may not be affected who [...] ill be evaluated in the Warren G. Magnuson Clinical C [...]
    Show what changed: Study description
    [...] ogg Dube (BHD) and hereditary leiomyomatosis and renal cell acarcinomacarcinoma (HLRCC) as well as familial renal cancer. Studies have led [...]

    Study Status, Study Description, Eligibilityv317

  3. Minor

    31 amendments

    31 re-verifications since 2024-06-22, no change to tracked fields

    v286-v316

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled. Affected individuals or individuals suspected of having a germline urologic malignant disorder will undergo periodic clinical assessment and genetic analyses for the purpose of: 1) definition and characterization of phenotype, 2) determination of the natural history of the disorder, and 3) genotype/phenotype correlation. Genetic linkage studies may be performed in situations in which the genetic basis of the disorder has not been elucidated.
Trial Details
NCT Number NCT00001238
Lead Sponsor National Cancer Institute (NCI)
Conditions Kidney Cancer, Urologic Malignant Disorders, Renal Cell Carcinoma, Familial Renal Cancer (FRC), Clear Cell Renal Cancer
Enrollment 5,000 participants
Start Date
Updated on ClinicalTrials.gov